Onesource Specialty Pharma · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Dr. Reddy's and other anchor partners have not received Canadian approvals for semaglutide despite market opening in January. Additional information requests from Health Canada have pushed timelines to February-May 2026, directly impacting Q3 revenue.
Current batch sizes are suboptimal and not commercially viable for large-scale production runs. Working with partners to scale up batch sizes requires regulatory approvals across multiple markets, creating execution uncertainty.
Oral GLP-1 formulations (like Eli Lilly's orforglipron) are gaining traction in obesity treatment. While management cited industry expectations of oral capturing max 25-33% of market, this wasn't addressed until analyst questioned it.
Company is selectively deferring take-pay contractual obligations for partners facing approval delays. While maintaining customer advances of Rs 250 crore, this creates some revenue visibility uncertainty until contracts are formally extended.
